In Vitro Development of Targeted Drugs and Nanoparticles
A special issue of Biomolecules (ISSN 2218-273X).
Deadline for manuscript submissions: closed (30 September 2022) | Viewed by 294
Special Issue Editor
2. Institute of Cardiology, Lithuanian University of Health Sciences, A. Mickeviciaus g. 9, LT44307 Kaunas, Lithuania
Interests: functionalized nanomaterials; targeted cancer treatment; cancer 2D and 3D models; transport in tumor microenvironment
Special Issue Information
Dear Colleagues,
During the last decades, there has been an increasing focus on the design and development of targeted drugs, including nanotherapeutics. Mostly nanosystems and targeted drugs are being developed for cancer therapy and diagnostics in order to reduce possible toxic effects, improve bioavailability and increase clinical efficiency. However, regardless of high expectations, nanomedicine still receives criticism mainly due to the lack of high affinity with respect to targeted tissue. Thus, more efficient strategies for targeting desirable tissues and combating resistance to therapy are needed. Currently, many actively targeting molecules are being investigated in various models in vitro and in vivo, providing new hope for more specific personalized therapy for many diseases.
This Special Issue on “In Vitro Development of Targeted Drugs and Nanoparticles” seeks high quality studies focusing on recent advances of targeted therapy and nanotechnology applied in personalized therapy areas. Topics include but are not limited to the following:
- Design of new molecules for targeted therapy and diagnostics;
- Development of targeted peptides/antibodies;
- Development of nanocarriers for personalized and precision medicine;
- Development of new nanomaterials for personalized therapy.
Dr. Vilma Petrikaitė
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Biomolecules is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2700 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- nanoparticles
- functionalized nanomaterials
- cancer therapy
- tumor microenvironment
- drug delivery
- nanomedicine
- nanotechnology
